Fundamental Pharma news and milestones
Fundamental Pharma: 17 headlines on record, 2 headlines in the last 90 days. Its story counts 2 milestones.
Data updated Nov 17, 2026 · Back to the company report
17Headlines
2In 90 days
2Milestones
Headlines
Nov 32026
Blog
FundaMental Pharma's CEO Dirk Beher discusses the unmet need in treatment-resistant depression and the potential of our lead candidate, FMP374, to make a difference to patients'…
Oct 162026
Blog
CMO Hans Eriksson speaks with pharmaphorum about the challenges of treating treatment-resistant depression and the potential for next-generation therapies to reduce treatment bur…
Aug 62026
Podcast
CMO Hans Eriksson highlights FundaMental Pharma's innovative approach to restoring neuroplasticity in treatment-resistant depression and its potential to address significant unme…
Jul 142026
Blog
Technology Networks - Investigational Drug Could Provide At-Home Treatment-Resistant Depression Care
CMO Hans Eriksson discusses the challenges of developing new treatments for treatment-resistant depression and the potential of dual-acting NMDA receptor modulation to address cu…
Jun 22026
Blog
Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in…
May 62026
Blog
Reflections on key discussions from Anglonordic Life Science 2026, including biotech investment trends and the importance of execution in today's market. Read Article The post ph…
May 12026
Podcast
A conversation covering treatment-resistant depression, current challenges in drug development, and the science behind FundaMental Pharma's research. Listen to the podcast The po…
Apr 302026
Blog
An interview exploring the unmet need in treatment-resistant depression and FundaMental Pharma's approach to developing next-generation therapies for patients. Watch the full fea…
Mar 242026
Blog
Industry experts at BioEurope Spring 2026 discuss the future of neuropsychiatric and neurodegenerative diseases drug development and how new technologies and biomarkers could hel…
Mar 182026
Blog
As part of Brain Awareness Week, FundaMental Pharma's CEO Dirk Beher discussed the potential of clinically validated pathways to address treatment-resistant depression. Read Arti…
Feb 172026
Press release · The Manila Times
Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD HEIDELBERG, Germany, Feb. 17, 2026 (…
Apr 11, 20242024
News · YahooFinance
PRESS RELEASE FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery e…
Mar 19, 20242024
News · markets.businessinsider.com
Feb 7, 20242024
News · YahooFinance
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatmen…
Sources: the outlets named on each headline, each story once
Milestones
Each milestone is dated by its source: registers, filings, the press
How to cite
Fundamental Pharma, News. Alion, Nov 17, 2026. https://alion.io/company/fundamentalpharma/news
